WGS
GeneDx Holdings Corp

4,469
Mkt Cap
$2.52B
Volume
1.14M
52W High
$170.87
52W Low
$55.17
PE Ratio
1,444.11
WGS Fundamentals
Price
$80.70
Prev Close
$87.08
Open
$84.02
50D MA
$114.12
Beta
1.47
Avg. Volume
722,901.85
EPS (Annual)
-$0.7339
P/B
8.61
Rev/Employee
$328,876.15
$3,667.03
Loading...
Loading...
News
all
press releases
BTIG Research Issues Pessimistic Forecast for GeneDx (NASDAQ:WGS) Stock Price
BTIG Research decreased their price target on GeneDx from $200.00 to $170.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat·21h ago
News Placeholder
More News
News Placeholder
GeneDx (NASDAQ:WGS) Trading 6.5% Higher on Earnings Beat
GeneDx (NASDAQ:WGS) Stock Price Up 6.5% After Earnings Beat...
MarketBeat·2d ago
News Placeholder
GeneDx Q4 Earnings Call Highlights
GeneDx (NASDAQ:WGS) reported fourth-quarter revenue of $121 million, bringing full-year 2025 revenue to $428 million, as management highlighted accelerating exome and genome testing demand and...
MarketBeat·2d ago
News Placeholder
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +27.27% and +1.50%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
GeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS
GeneDx (NASDAQ:WGS - Get Free Report) issued its earnings results on Monday. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.03...
MarketBeat·2d ago
News Placeholder
GeneDx Slides To Net Loss In Q4; Reaffirms FY26; Shares Up In Pre-market
(RTTNews) - GeneDx Holdings Corp. (WGS), a healthcare company, on Monday reported net loss in the fourth quarter despite higher revenue compared with the previous year...
Nasdaq News: Markets·2d ago
News Placeholder
GeneDx Holdings Q4 Earnings Report: What Investors Need to Know
read more...
Benzinga·2d ago
News Placeholder
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full...
Business Wire·2d ago
News Placeholder
Telemark Asset Management LLC Invests $12.93 Million in GeneDx Holdings Corp. $WGS
Telemark Asset Management LLC acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·3d ago
News Placeholder
GeneDx (NASDAQ:WGS) Shares Down 8% - Here's What Happened
GeneDx (NASDAQ:WGS) Stock Price Down 8% - Should You Sell...
MarketBeat·4d ago
<
1
2
...
>

Latest WGS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.